Case stories & studies

Lipopolysaccharide adsorption in combined therapy of patients with severe sepsis

Our experience of LPS adsorption with the Alteco LPS Adsorber shows evidence of potential efficacy of this method in combined therapy for severe gram-negative sepsis. Further investigations are required.

A lipopolysaccharide adsorber in adult cardiopulmonary bypass: a single center randomized controlled pilot trial

This study demonstrated the Alteco LPS Adsorber to be safe in a complex cardiac surgery setting.

Clinical effects of adsorption of lipopolysaccharide in the treatment of Gram-negative severe sepsis

A statistically significant improvement in hemodynamics, oxygenation, and reduced markers of endotoxemia in group therapy with Alteco LPS Adsorber compared with traditional therapy. These effects were attributed with the removal of endotoxin from the systemic circulation. Only in one case using hemofiltration for acute renal failure in the study group (in the reference group in all patients), 28-day mortality was 16.7% and 66.7% respectively. Negative effects were negligible.

Clinical experience with lipopolysaccharide adsorber in cancer patients with severe sepsis and septic shock

After LPS adsorption with Alteco LPS Adsorber, the LPS level in patient serum was significantly reduced. Simultaneously, concentrations of some cytokines (IL-6, TNFβ, IL-8) were reliably decreased. But the Alteco LPS Adsorber probably does not eliminate soluble receptors like sCD14 and RIL-1 from blood. So the LPS adsorption may represent a significant improvement in the treatment of cancer patients with severe gram-negative sepsis and septic shock.

A New Endotoxin Adsorber in Septic Shock: Observational Case Series

Two-hour hemoperfusion with Alteco LPS Adsorber was initiated in patients with septic shock and endotoxemia. Controls were matched for age, focus and severity of illness. Alteco LPS Adsorber treatment was associated with a decrease in noradrenaline dose, decrease in SOFA scores and LPS concentrations.

Use of an endotoxin adsorber in the treatment of severe abdominal sepsis

After LPS adsorption with Alteco LPS Adsorber, the level of LPS in the patient's bloodstream was almost eliminated: from 1.44 EU/ml before treatment to 0.03 EU/ml post treatment. The procalcitonin level and inflammatory cytokines were concurrently reduced. Also, an obvious improvement in the status of the patient's hemodynamics was seen. Forty-five days after treatment the patient is still alive. LPS adsorption may represent a significant improvement in the treatment of gram-negative sepsis and further studies are planned.

Clinical experience with a novel endotoxin adsorption device in patients undergoing cardiac surgery

No adverse events were encountered when the Alteco LPS Adsorber was used in the circuit. Blood flow through the device was easily monitored and kept at the desired level. The Alteco LPS Adsorber can be used safely and is easy to handle in the bypass circuit. No complications related to the use of the device were noted.

Selective adsorption of endotoxin in the complex treatment of patients with severe sepsis

A session with Alteco LPS Adsorber caused a significant drop in the blood level of endotoxin and procalcitonin and it was accompanied by a trend toward better hemodynamics and lung gas exchange and alleviated organ dysfunction.